ATE159953T1 - Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 - Google Patents

Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6

Info

Publication number
ATE159953T1
ATE159953T1 AT94918396T AT94918396T ATE159953T1 AT E159953 T1 ATE159953 T1 AT E159953T1 AT 94918396 T AT94918396 T AT 94918396T AT 94918396 T AT94918396 T AT 94918396T AT E159953 T1 ATE159953 T1 AT E159953T1
Authority
AT
Austria
Prior art keywords
cell
epitope
cd44v6
cells
hermes
Prior art date
Application number
AT94918396T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Original Assignee
Biotie Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22141703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE159953(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Oy filed Critical Biotie Therapies Oy
Application granted granted Critical
Publication of ATE159953T1 publication Critical patent/ATE159953T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94918396T 1993-06-18 1994-06-16 Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 ATE159953T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7806393A 1993-06-18 1993-06-18

Publications (1)

Publication Number Publication Date
ATE159953T1 true ATE159953T1 (de) 1997-11-15

Family

ID=22141703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918396T ATE159953T1 (de) 1993-06-18 1994-06-16 Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6

Country Status (13)

Country Link
US (1) US5616468A (de)
EP (1) EP0703989B1 (de)
JP (1) JPH08511419A (de)
AT (1) ATE159953T1 (de)
AU (1) AU678487B2 (de)
CA (1) CA2165461A1 (de)
DE (1) DE69406664T2 (de)
DK (1) DK0703989T3 (de)
ES (1) ES2110764T3 (de)
GR (1) GR3025759T3 (de)
IL (1) IL110070A0 (de)
WO (1) WO1995000658A1 (de)
ZA (1) ZA944383B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134982A1 (de) * 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
JP3431922B2 (ja) * 1992-06-09 2003-07-28 オイ バイオティエ セラピーズ リミテッド 炎症性疾患および自己免疫疾患の診断用組成物および診断方法
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
ES2533002T3 (es) * 2004-03-10 2015-04-06 Creighton University Receptores estrogénicos y métodos de uso
US20050214880A1 (en) * 2004-03-26 2005-09-29 University Of Miami Salivary soluble CD44: a molecular marker for head and neck cancer
EP2041299A4 (de) * 2006-07-14 2010-01-13 Aviva Biosciences Corp Verfahren und zusammensetzungen für den nachweis seltener zellen aus einer biologischen probe
US20080057505A1 (en) * 2006-07-14 2008-03-06 Ping Lin Methods and compositions for detecting rare cells from a biological sample
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
CN103648517B (zh) * 2011-03-24 2016-04-20 纽瑞姆制药（1991）有限公司 神经保护肽
RU2017104284A (ru) 2014-07-15 2018-08-15 Йиссум Рисеч Девелопмент Компани Оф Зе Хебрю Юниверсити Оф Джерусалем Лтд. Выделенные полипептиды cd44 и их применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014510A1 (de) 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE4134982A1 (de) 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Also Published As

Publication number Publication date
DE69406664D1 (de) 1997-12-11
AU6972694A (en) 1995-01-17
DE69406664T2 (de) 1998-06-04
IL110070A0 (en) 1994-10-07
EP0703989B1 (de) 1997-11-05
DK0703989T3 (da) 1998-02-09
AU678487B2 (en) 1997-05-29
CA2165461A1 (en) 1995-01-05
GR3025759T3 (en) 1998-03-31
WO1995000658A1 (en) 1995-01-05
US5616468A (en) 1997-04-01
ZA944383B (en) 1995-03-03
JPH08511419A (ja) 1996-12-03
ES2110764T3 (es) 1998-02-16
EP0703989A1 (de) 1996-04-03

Similar Documents

Publication Publication Date Title
ATE159953T1 (de) Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
Meigel et al. Dermal architecture and collagen type distribution
Bukovský et al. The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube.
Sappino et al. Smooth muscle differentiation in scleroderma fibroblastic cells.
Fogel et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma
Liu et al. KAI1/CD82, a tumor metastasis suppressor
Weiss et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function
Sasaki et al. Expression and distribution of laminin α1 and α2 chains in embryonic and adult mouse tissues: an immunochemical approach
Matsuura et al. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma.
Bardin et al. S‐Endo 1, a pan‐endothelial monoclonal antibody recognizing a novel human endothelial antigen
Sers et al. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread
Gould et al. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast
Hamilton et al. Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen
Bordessoule et al. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67
Cagnano et al. Expression of ligands to NKp46 in benign and malignant melanocytes
Kunz et al. Epidermal expression of the calcium binding surface antigen 27E10 in inflammatory skin diseases
Posnett et al. A membrane antigen (HC1) selectively present on hairy cell leukemia cells, endothelial cells, and epidermal basal cells.
Tanaka et al. Differential expression of· 1 (IV),· 2 (IV),· 5 (IV) and· 6 (IV) collagen chains in the basement membrane of basal cell carcinoma
Schmoeckel et al. Structure of basement membranes in malignant melanoma and nevocytic nevi
Tiitta et al. Tenascin in inflammatory conditions and neoplasms of the urinary bladder
Lohi et al. Expression of type IV collagen α1 (IV)–α6 (IV) polypeptides in normal and developing human kidney and in renal cell carcinomas and oncocytomas
Patel et al. Expression of CD44 molecules and CD44 ligands during human thymic fetal development: expression of CD44 isoforms is developmentally regulated
Georgolios et al. THE ROLE OF CD�� ADHESION MOLECULE IN ORAL CAVITY CANCER
Rudland et al. Characterization of human mammary cell types in primary culture: immunofluorescent and immunocytochemical indicators of cellular heterogeneity
Goepel et al. Tenascin—a marker for the malignant potential of preinvasive breast cancers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee